Eagle IP is Recognized in IAM Patent 1000 as a Top Tier Firm

July 2022

We are delighted to share that Eagle IP has been recognized by IAM Patent 1000 as a Highly-Recommended Firm for our expertise in Prosecution. Our President Dr. Jacqueline Lui and Vice President and Principal Ms. Jennifer Che are also ranked as Leading Individuals in the Hong Kong chapter. Regarding Dr. Lui, IAM highlighted her strength in diverse areas, stating “[Dr. Lui’s] experience in the United States, Hong Kong and Singapore has made her well versed in US IP law and international standards.” IAM also recognized Jennifer Che’s biopharma expertise, saying “[h]er in-house experience at Vertex Pharmaceuticals and Axcella has formed her acute awareness of the commercial considerations that are vital to a business.”

We are honored to be listed in this highest category among many other great firms in Hong Kong. We are thankful for IAM’s recognition of our deep expertise in US and China “cross-border” IP, our stellar life science team, and our strength in crafting and executing sophisticated and creative patent strategies.

In this current, seemingly more and more divided world, we seek to live out our core value of being a “bridge” and bringing people and innovations together. While it goes without saying that we never stop refining our knowledge and expertise in IP, we also seek to use our unique position in the middle to better understand and relate to all sides of the “bridge”. We hope to bring people together to collaborate, with the ultimate goal of innovating forward in synergy to help solve the many problems in this current world.


Eagle IP is a top-tier boutique patent firm with a unique mix of experienced US and Chinese patent professionals with significant cross-border knowledge and experience. Our technically expertise covers wide range of technologies including, but not limited, to life sciences, biotechnology, medicine, and pharmaceuticals. We have years of experiences in drafting and prosecuting life sciences patent applications involving biological deposits, sequence listings, small and large molecules, drug discovery and development, and many others.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.